Advanced Medical Solutions reports poor US sales

Advanced Medical Solutions has revealed its annual profits will be at the 'lower end' of market expectations.

Advanced Medical Solutions has revealed its annual profits will be at the 'lower end' of market expectations.

The news was unveiled Thursday in the UK-based global medical technology company's trading update which reported lower-than-expected sales of their LiquidBand product in the US market.

The woundcare group said it was disappointed with its progress in the second half of 2012 after failing to sell as much they had hoped of the product, a skin adhesive for wounds.

"With the gains made across a number of fronts being offset to some extent by the performance of LiquiBand in the US Acute Care hospital sector and continued pressure on foam roll-stock, overall indications for the full year are that AMS will be at the lower end of market expectation for pre-tax profits," the company said in a statement.

The organisation said the overall performance of LiquiBand in the US has been mixed with success in the Alternative Site sector but trouble in targeting the larger Acute Care hospital sector.

"We are actively reviewing the most effective strategy for accessing and gaining market share in this important sector. AMS's roll-stock foam revenues will also be lower than in the prior year, as previously highlighted in the interim statement," the company stated.

However the company said it has made progress with ActivHeal, silver alginate and the converted foam portfolios. It is also expecting growth in existing businesses and from its Resorba brands.

Advanced Medical Solutions has a £121.69m market capitalisation. Shares fell 13.77% to 59.50p at 11:35 Thursday.

RD

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020

Most Popular

Why we won’t see a house-price crash in 2021
House prices

Why we won’t see a house-price crash in 2021

Lockdown sent house prices berserk as cooped up home-workers fled for bigger properties in the country. And while they won’t rise quite as much this y…
18 Jan 2021
Prepare for the end of the epic bubble in US stocks
US stockmarkets

Prepare for the end of the epic bubble in US stocks

US stocks are as expensive as they’ve ever been. How can you prepare your portfolio for a bubble bursting?
18 Jan 2021
The best investment trusts to buy for 2021
Investment trusts

The best investment trusts to buy for 2021

Sectors ranging from emerging markets to student accommodation look poised to do well this year, says David Stevenson, as he picks the best investment…
19 Jan 2021